Document is current

Article History

Received: 5 September 2024

Accepted: 3 October 2025

First Online: 4 November 2025

Declarations

:

: All study participants provided informed consent, including permission to publish their anonymized responses. This study was conducted in accordance with the ethical principles of Declaration of Helsinki and are consistent with Good Pharmacoepidemiology Practices and applicable local laws and regulations.

: Individual participant data, including quotes from participants, have been anonymized, and the authors affirm that participants provided consent to having their data published.

: THG is an employee and stockholder of Eli Lilly and Company. KK is an employee of RTI Health Solutions, which received funding from Eli Lilly and Company to conduct the study. BB is an employee of RTI Health Solutions, which received funding from Eli Lilly and Company to conduct the study. SM is an employee of RTI Health Solutions, which received funding from Eli Lilly and Company to conduct the study. REM is an employee and stockholder of Eli Lilly and Company. PJ is an employee and stockholder of Eli Lilly and Company. MCD reports consulting fees from AbbVie Inc., Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genentech (Roche), Gilead Sciences Pty. Ltd., Janssen Pharmaceuticals, Johnson & Johnson, Merck, Pfizer Inc., Prometheus Biosciences, Sphyre, Takeda Pharmaceutical Company, and UCB Pharma SA; contracted research for AbbVie Inc. and Janssen Pharmaceuticals; stock interest in Trellus Health Inc.; and licensing fees from Takeda Pharmaceuticals USA. To ensure data integrity and independence in analyses and interpretation, all data collection and analyses were conducted independently by the research team of RTI Health Solutions, an independent research organization.